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Background: The neuroendocrine protein 7B2 blocks the aggregation of certain secreted proteins.
Results: 7B2 co-localizes with protein aggregates in Parkinson and Alzheimer disease brains; blocks the fibrillation of A1–40,
A1–42, and -synuclein; and blocks A1–42-induced Neuro-2A cell death.
Conclusion: 7B2 inhibits the cytotoxicity of A1–42 by modulation of oligomer formation.
Significance: 7B2 is a novel anti-aggregation secretory chaperone associated with neurodegenerative disease.
Neurodegenerative diseases such as Alzheimer (AD) and Par-
kinson (PD) are characterized by abnormal aggregation of mis-
folded-sheet-rich proteins, including amyloid- (A)-derived
peptides and tau in AD and -synuclein in PD. Correct folding
and assembly of these proteins are controlled by ubiquitously
expressed molecular chaperones; however, our understanding
of neuron-specific chaperones and their involvement in the
pathogenesis of neurodegenerative diseases is limited. We here
describe novel chaperone-like functions for the secretory pro-
tein 7B2, which is widely expressed in neuronal and endocrine
tissues. In in vitro experiments, 7B2 efficiently prevented fibril-
lation and formation of A1–42, A1–40, and-synuclein aggre-
gates at a molar ratio of 1:10. In cell culture experiments, inclu-
sion of recombinant 7B2, either in the medium of Neuro-2A
cells or intracellularly via adenoviral 7B2 overexpression,
blocked the neurocytotoxic effect of A1–42 and significantly
increased cell viability. Conversely, knockdown of 7B2 by RNAi
increased A1–42-induced cytotoxicity. In the brains of APP/
PSEN1 mice, a model of AD amyloidosis, immunoreactive 7B2
co-localized with aggregation-prone proteins and their respec-
tive aggregates. Furthermore, in the hippocampus and substan-
tia nigra of human AD- and PD-affected brains, 7B2 was highly
co-localizedwithAplaques and-synuclein deposits, strongly
suggesting physiological association. Our data provide insight
into novel functions of 7B2 and establish this neural protein as
an anti-aggregation chaperone associated with neurodegenera-
tive disease.
Excessive aggregation ofmisfolded proteins is a common fea-
ture in the pathophysiology of many neurodegenerative disor-
ders such as Alzheimer disease (AD),2 Parkinson disease (PD),
and amyotrophic lateral sclerosis (1). AD, for example, is neu-
roanatomically characterized by extracellular plaques com-
posed of amyloid precursor protein (APP)-derived amyloid-
(A) peptides (2) and intracellular neurofibrillary tangles made
up of hyperphosphorylated tau (3). Similarly, Lewy bodies, the
hallmark of PD, are large cytosolic inclusion bodies composed
of aggregated -synuclein protein within dopaminergic neu-
rons of the substantia nigra (4). Although the exact pathogenic
role of these various aggregates is incompletely understood, it
has been hypothesized that aggregation of A peptides into
oligomers andplaques results in a neurotoxic environment, dis-
rupting cell function and leading to the loss of specific neuronal
populations (5).
In the search for the underlying molecular mechanisms for
these toxic effects, chaperone proteins have been implicated as
important modulators of abnormal protein folding and aggre-
gation in various neurodegenerative diseases (6). For example,
several ubiquitously expressed molecular chaperones within
the heat shock (e.g.HSP90,HSP70, andHSP27) and-crystallin
protein families have been shown to be associatedwith protein-
misfolding diseases (7–10). The secreted chaperone clusterin
has also been implicated in neurodegenerative disease
(reviewed in Refs. 11 and 12). However, our understanding of
the role of chaperone-mediated quality control machinery in
neurodegenerative disease is still limited, and the question of
whether chaperones other than heat shock proteins, crystallins,
and clusterinmight contribute to plaque pathogenesis or clear-
ance remains open.
The secretory protein 7B2, known best for its role as a pro-
hormone convertase 2 (proPC2)-binding protein (13, 14), is
universally expressed in endocrine, neural, andneuroendocrine
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cells, which all possess a regulated secretory pathway (15, 16).
Because expression of 7B2 in the brain is not confined to con-
vertase-containing neurons (15), it seems likely that 7B2 must
possess physiological functions exceeding its involvement in
neuropeptide synthesis. Early reports indicated that 7B2 could
be distantly related to a subclass ofmolecular chaperones called
chaperonins (17). 7B2 blocks the formation of proPC2 oligo-
mers and aggregates (18) as well as IGF-1 aggregates (19), dem-
onstrating that 7B2 functions as a post-folding and post-secre-
tion chaperone. Moreover, independent discovery studies
searching for biomarkers of early-onset AD, PD, and amyo-
trophic lateral sclerosis have identified 7B2 as a potential can-
didate protein (20–23).
On the basis of findings showing association of 7B2 with
neurodegenerative disease and the known role of 7B2 in block-
ing proPC2 aggregation, we investigated the hypothesis that
neuronal 7B2 could function to block neurodegenerative dis-
ease-related protein aggregation. We tested the action of 7B2-
derived proteins on the cytotoxicity and fibrillation of the
A1–42 andA1–40 peptides and-synuclein.Our experiments
using animal, cellular, and in vitro approaches provide collec-
tive support for the idea that 7B2 represents a novel neuropro-
tective chaperone.
EXPERIMENTAL PROCEDURES
AnimalModels—All studies were conducted followingUniver-
sity of Houston-approved Institutional Animal Care and Use
Committee protocols. B6C6-Tg(APPswe,PSEN1dE9)85Dbo/J
(APP/PSEN1; The Jackson Laboratory) mice (12 months old)
were used in this study. APP/PSEN1 double transgenic mice
express a chimeric mouse/human APP (Mo/HuAPP695swe)
and a mutant human presenilin-1 (PS1-dE9) protein, both
directed to CNS neurons; these familial mutations are strongly
associated with early-onset AD. The mice were killed, and the
brains were fixed with Accustain (Sigma) and subjected to
paraffin processing. Brains were sectioned using a Leica
microtome at 10-m intervals.
Immunohistochemistry ofMouse Brain Tissue—Coronal sec-
tions (10 m) of formalin-fixed tissue were deparaffinized and
subjected to an antigen retrieval protocol using Aqua DePar
and Reveal antigen retrieval solutions in aDecloakingChamber
system (Biocare Medical). Following antigen retrieval, some
sections were briefly stained with methoxy-X04 (1 M), fol-
lowed by extensive washing to visualize dense core amyloid
pathology. Other sections were treated with an avidin/biotin
blocking kit (Vector Laboratories, Burlingame, CA), followed
by treatment with 5% normal goat serum in Tris-buffered
saline containing 0.5% Tween 20 (TBST) for 20min. Sections
were incubated with polyclonal rabbit anti-7B2 antiserum
(LSU13BF; 1:200) for 1 h and washed with TBST. Sections
were incubated with biotinylated goat anti-rabbit antibody
(Vector Laboratories) for 30 min, washed with TBST, and then
incubated with Texas Red-labeled avidin DCS (Vector Labora-
tories) for 10 min. Sections were then washed with TBST. For
co-localization, tissue was reblocked using the avidin/biotin
blocking kit, subjected to a second round of blocking, and incu-
bated with a second round of antibodies (anti-A1–42; 12F4;
1:250; Covance), followed by washing and incubation with flu-
orescein-avidin (Vector Laboratories) for 10 min. The sections
were then washed extensively with Tris-HCl, mounted using
VECTASHIELDmedium, and viewed under an Olympus IX61
DSU confocal microscope. Images were processed with Neuro-
lucida (MicroBrightField, Inc., Williston, VT).
HumanBrain Tissues—AnAD-affected human brain sample
(73-year-old female donor) and a control sample (72-year-old
male donor, naturally deceased) containing the hippocampus
and a PD-affected humanmidbrain sample containing the sub-
stantia nigra of a 89-year-old male donor were obtained from
the NICHD Brain and Tissue Bank for Developmental Disor-
ders of the University of Maryland, Baltimore. Formalin-fixed
brain samples at either the level of the cortex or mesencepha-
lon, respectively, were cryoprotected in 30% sucrose, deep-fro-
zen in isopentane over dry ice (1 min), and stored at 80 °C
until required.
Immunohistochemistry of Human Brain Tissue—Coronal
sections (16m) containing the hippocampus (AD and control
samples) and the substantia nigra (PD sample) were processed
using a Leica cryostat, collected on Superfrost Plus object slides
(Fisher Scientific, Hampton, NH), and treated with blocking
solution containing 3% BSA in 0.5% Triton X-100 in PBS
(0.5% PBST) for 1 h to block nonspecific reactions. Sections
were then incubated with polyclonal rabbit anti-7B2 antiserum
(LSU13BF; 1:250) and monoclonal mouse anti--synuclein
antiserum (1:150; BD Biosciences) (24) in blocking solution
overnight at 4 °C. Sections were rinsed briefly with 0.25% PBST
and PBS and incubated with Cy3-conjugated (Exmax 550 nm
and Emmax 570 nm) goat anti-rabbit (A10520; 1:200; Invitro-
gen) and Cy2-conjugated (Exmax  492 nm and Emmax  510
nm) donkey anti-mouse (AP124J; 1:250; Millipore) secondary
antibodies in blocking solution containing H33342 (Exmax 
350 nm and Emmax  461 nm) nuclear/DNA staining reagent
(1:10,000; ALX-620-050, Axxora LLC, SanDiego, CA) for 2 h at
room temperature. Sections were rinsed with PBS and cover-
slipped with Fluoromount G (Electron Microscopy Sciences,
Hatfield, PA). Immunofluorescence was visualized using an
Olympus BX61 confocal microscope and a Nikon Eclipse
TE2000-E epifluorescence microscope. Images of immunore-
activity were merged by color channel overlay using micro-
scope-specific image processing software (Olympus FluoView
and Nikon MetaView). Anatomical localization of immunore-
activity within the brain was annotated according to the Allen
Human Brain Atlas Data Portal and Gray’s Anatomy of the
Human Body (54).
A1–42 Oligomer Preparation—A1–42 peptide films were
resuspended in Me2SO at a concentration of 5 mM, and the
peptide solutions were sonicated in a water bath sonicator for
10min at room temperature. The solutionswere then diluted to
a final concentration of 100Mwith Ham’s F-12medium (phe-
nol red-free; BIOSOURCE) and incubated at 4 °C for 24 h to
formA1–42 oligomers (25). In some experiments, A1–42 olig-
omerswere added to themediumofNeuro-2A cells in the pres-
ence of vehicle (Ham’s F-12), recombinant 7B2 (see below),
-crystallin (Sigma), or -lactalbumin (14.2 kDa; L4385,
Sigma).
Cell Proliferation and Viability Assay—Neuro-2A cells were
seeded at 5  103/well in 96-well plates and left to attach at
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37 °C overnight. Subsequently, cells were treated with 10 M
A1–42 oligomers in the presence or absence of 2–4 M 7B2,
-lactalbumin as a negative control, or vehicle (Ham’s F-12) for
48 h. Cell survival was measured at the indicated times by add-
ing 10 l of a 1:3 (v/v) dilutedWST-1 cell proliferation reagent
stock solution (Roche Applied Science). Samples were incu-
bated for 60–240min, and absorbance at 450 nmwasmeasured
with a SpectraMax M2 fluorometer (Molecular Devices,
Sunnyvale, CA) using a 690-nm reference filter. After subtrac-
tion of the background absorbance, the mean values of the
untreated control cells were set as 100%. In addition, cell viability
was assessed by labeling cells with calceinAM (2M; Exmax 485
nm and Emmax 530 nm; L3224, Invitrogen), and fluorescence
was measured using the SpectraMax M2 fluorometer. Repre-
sentative photomicrographs were taken using the Nikon
Eclipse TE2000-E epifluorescence microscope.
Adenoviral Infection of Neuro-2A Cells—To infect
Neuro-2A cells with 7B2-encoding adenovirus (26), cells
were seeded at 5  103/well into 96-well plates. Replicate
wells were trypsinized and counted again the following day for
calculation of adenoviral multiplicity of infection. Cells were
washed twice with PBS, and 7B2 or control (-galactosidase-
encoding) adenovirus was diluted to achieve a multiplicity of
infection of 1 in PBS in a final volume of 50l/well. The diluted
adenovirus solution was added directly to cells in growth
medium, and the plates were swirled to mix well and incubated
for 30 min to permit adenoviral infection. Fifty l of high glu-
coseDMEMcontaining 2% fetal bovine serumwere then added
to each well. Adenovirus-infected cells were incubated for 36 h
at 37 °C in a CO2 incubator. The mediumwas then changed to
DMEM containing 10 M A1–42 for 48 h. Cell viability was
assessed at this time using theWST-1 cell proliferation assay
as described above.
7B2 RNAi Experiments—Three different specific sequences
of Stealth siRNA (Invitrogen)were designed for themurine 7B2
mRNA sequence (MSS237887, MSS237888, and MSS237889).
Following assessment of individual knockdown efficiencies, the
most effective siRNA, MSS237887, was deployed. A control
scrambled sequence was designed to have the sameGC content
(46-2000, Invitrogen). Neuro-2A cells grown in 96-well plates
were transfected sequentially with the respective siRNA at 100
nMon the first day and 200 nMon the second day using 5l/well
Lipofectamine 2000 (Invitrogen). The medium was then
changed overnight to DMEM containing 4 MA1–42 for 48 h.
Transfection efficiency in Neuro-2A cells was monitored
using a scrambled siRNA sequence conjugated to fluorescein
(N2100S, New England Biolabs). The total cell number was
determined by counterstaining with 5 g/ml Hoechst 33342
(Invitrogen) for 45min and subsequent examination by fluores-
cence microscopy. Cell viability was assessed using the WST-1
cell proliferation assay as described above.
Cellular Uptake of 7B2 and A1–42 into Neuro-2A Cells—
Neuro-2A cells were grown overnight in 24-well plates on cov-
erslips in DMEM supplemented with 10% (v/v) fetal bovine
serum.On the next day, 250 nMAlexa Fluor 647-labeledA1–42
(64161, AnaSpec, Fremont, CA) and recombinant 7B2 were
added to the medium, and cells were incubated at 37 °C in 5%
CO2 for 24 h. Neuro-2A cells were then treated with 4% para-
formaldehyde for 20 min and incubated with blocking solution
containing 3% BSA in 0.5% PBST for 1 h to block nonspecific
reactions. Exogenous 7B2was then visualized usingAlexa Fluor
488-labeled anti-His tag antibody (16-254, Millipore). Cells
were rinsed briefly with 0.25% PBST and PBS containing DAPI
(Exmax 358 nm and Emmax 461 nm) nuclear/DNA staining
reagent (1:10,000; D1306, Invitrogen) for 2 h at room tempera-
ture. Cells were then rinsed with PBS and mounted on object
slides with Fluoromount G. Immunofluorescence was visual-
ized using the Olympus BX61 confocal microscope and the
Nikon Eclipse TE2000-E epifluorescence microscope.
Peptide Synthesis and Purification of Recombinant 7B2-de-
rived Peptides—An automated bench-top simultaneous mul-
tiple solid-phase peptide synthesizer (PSSM-8 system, Shi-
madzu) was used for the synthesis of 7B2 peptide 86–121 by
the N-(9-fluorenyl)methoxycarbonyl (Fmoc) procedure in
NovaSyn TGR resin (Novabiochem, San Diego, CA) as
described previously (27). Themolecularmass and purity of the
synthetic peptide were verified by reverse-phase HPLC and
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (TofSpec E, Micromass). Recombinant His-
tagged 27- and 21-kDa 7B2 and 7B2 peptides 30–150 and
68–150 were prepared using the QIAexpress system (Qiagen).
Primers were designed as described previously (27). PCR frag-
ments were cloned into pQE30, and sequences were verified by
DNA sequencing. Proteins were expressed in Escherichia coli
XL1-Blue (Stratagene) and purified with the guanidine HCl/
refolding method as described previously (28).
Thioflavin T Assay—Fibrillation of amylogenic peptides
(A1–42, A1–40, and -synuclein) in the presence and absence
of 7B2 was measured by thioflavin T (ThT) fluorescence assays
in 96-well plates (29). Recombinant A1–42 and A1–40 were
purchased from Biopeptide Co. (San Diego, CA), and -sy-
nuclein was expressed and purified as described (30). A1–40
and A1–42 were diluted in 0.5% Me2SO and 0.5 M Tris-HCl
buffer (pH 7.4; 1 mg/ml) and then diluted into 40 M ThT
solutions (in quadruplicate) containing or lacking the various
forms of 7B2 in a total volume of 100l.-Synuclein fibrillation
assays were performed in PBS (pH 7.4) and included one 3/32-
inch diameter polytetrafluoroethylene bead (McMaster-Carr,
Santa Fe Springs, CA) per well. The final concentrations of
fibrillogenic peptideswere 20M forA1–40 andA1–42 and 44
M for -synuclein. Plates were incubated at 37 °C with agita-
tion on a microtiter plate shaker (Glas-Col, Terre Haute, IN),
with the speed set to 30 for the time periods indicated. Controls
for the fibrillation reactions included carbonic anhydrase
(molecular mass of29 kDa; C5024, Sigma), a protein chosen
because of its comparable weight to 7B2. The development of
fibrillation was monitored by measuring the fluorescence of
ThT using the SpectraMaxM2 fluorometer at 485 nm emission
(444 nm excitation).
Dot Blot Analysis—Fibrillated A1–42 samples were centri-
fuged, transferred to a nitrocellulose membrane, and subjected
to anti-A Western blot analysis. A1–42 fibrillation assays
were performed as described above. At 48 h, samples of A1–42
control reactions and of reactions incubatedwith 27- or 21-kDa
7B2 were removed. One-third of each reaction was used as a
reference for the total reaction, whereas the remainingmaterial
7B2 Inhibits Protein Aggregation
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was centrifuged for 30 min at 20,000  g (4 °C) to separate
soluble material containing mono- and oligomeric A1–42 and
pelletablematerial containing heavy fibrils. An appropriate vol-
ume of PBSwas added to the total, supernatant, and pellet sam-
ples to make the volume up to 100 l. Ten l of these reactions
were transferred to a 0.2-m nitrocellulose membrane (Bio-
Rad) and air-dried, and the membrane was then blocked with
0.5% BSA and 0.2% goat serum in Tris-buffered saline contain-
ing 0.3% Triton X-100. The blot was incubated with monoclo-
nal anti-A antiserum (6E10; 1:1000; Covance) in blocking
buffer overnight at 4 °C. On the following day, the blots were
washed three times with TBS containing 0.05% Tween 20, fol-
lowed by incubation at room temperature for 1.5 h using horse-
radish peroxidase conjugate as the secondary antibody. Blots
were incubated with SuperSignalWest Pico chemiluminescent
substrate (Pierce) for 1min, and chemiluminescent bands were
visualized using HyBlot CL autoradiography film (Denville Sci-
entific Inc.). Dot intensities were analyzed using NIH ImageJ
densitometric analysis software and displayed as mean inten-
sity (n 3/group), and the ratios between the supernatant and
pellet samples were calculated.
Transmission Electron Microscopy—Specimens (incubated
for 72 h)were adsorbed onto 400-mesh Formvar-coated copper
grids and negatively stained with 2% phosphotungstic acid (pH
7). After wicking off excess solution, grids were air-dried and
examined in a Tecnai T12 transmission electron microscope
(FEI) operated at 80 kV. Digital images were acquired using an
AMT bottom-mount CCD camera and AMT600 software.
Luciferase Refolding Assay—A possible ATP-dependent,
chaperone-like protein-refolding function of 7B2 was tested by
incubating unfolded firefly luciferasewith recombinant 21- and
27-kDa 7B2, followed by measurement of regained luciferase
activity. A 10 M solution of Photinus pyralis luciferase (Roche
Applied Science) was resuspended in 0.5 M Tris acetate buffer
(pH 7.5), followed by denaturation in 6 M guanidine hydrochlo-
ride and 5 mM DTT for 30 min at room temperature. The gua-
nidine hydrochloride solution was dialyzed against PBS over-
night at 4 °C. Refolding reactions were performed by diluting
denatured luciferase 1:100 in refolding buffer (25 mM HEPES
(pH 7.4), 5 mMMgCl2, 50 mM KCl, 5 mM DTT, and 3 mM ATP)
in the presence or absence of recombinant 21- or 27-kDa 7B2 (4
M) using BSA as a negative control and human recombinant
HSP70 (Enzo Life Sciences, Farmingdale, NY) as a positive con-
trol. The incubation with 7B2 was performed for 3 h at room
temperature, followed by 1:10 dilution of reactions into lucifer-
ase assay buffer (Promega). Luciferase activity was determined
by measurement of luciferin bioluminescence using a Flex-
Station 3 microplate reader (Molecular Devices). Protein refold-
ing was defined as recovery of luciferase activity expressed as a
percent of the activity of native luciferasemeasured at the same
concentration.
Statistical Analysis—Data were analyzed with one- or two-
way analysis of variance, followed by the Student-Newman-
Keuls multiple comparison test, as appropriate, using a statisti-
cal software package (SigmaStat, Systat Software, Inc., San Jose,
CA). Data not meeting a normal distribution were analyzed
using one-way analysis of variance, followed by the Newman-
Keulsmultiple comparison test. p 0.05 was considered statis-
tically significant.
RESULTS
7B2 Co-localizes with A1–42 Amyloid Plaque Pathology in
APP/PSEN1 Mice—To assess a possibly physiologically rele-
vant relationship between 7B2 andproteins involved in amyloid
plaque pathology, we performed an immunohistochemical co-
localization study using brains from12-month-oldAPPmutant
mice. Immunoreactive 7B2 was observed in association with
A1–42 immunoreactivity throughout the brain. Within the
hippocampus, 7B2 immunoreactivity strongly overlapped with
staining for A1–42 (Fig. 1A). Furthermore, within the hip-
pocampus, 7B2 immunoreactivity strongly co-localized with
staining for A1–42 dense core plaque pathology, as demon-
strated by its apparent overlap with methoxy-X04-positive
A1–42 aggregates (Fig. 1B).
7B2 Co-localizes with A1–42 Deposits in Human AD Hip-
pocampus and with -Synuclein-rich Lewy Bodies within the
Substantia Nigra of a PD Patient—7B2 immunoreactivity was
detected throughout the extent of the human brain, including
somata and dendritic and axonal branches in neurons of the
cortex and mesencephalon (data not shown). Within the hip-
pocampus of a humanADbrain, 7B2 strongly co-localized with
extracellular A1–42 deposits (Fig. 2A). 7B2 strongly co-local-
ized with -synuclein-positive cytoplasmic inclusions (Lewy
bodies) in neurons within the substantia nigra of a PD brain
(Fig. 2B). Although80%of the observed 7B2 co-localizedwith
-synuclein immunoreactivity, scattered-synuclein immuno-
reactivity could be observed that was not 7B2-immunoreactive
(arrowhead with asterisk). In a similar hippocampus sample
from a healthy human control, 7B2 staining was found near cell
nuclei, indicating intracellular localization, whereas no signifi-
cant staining for A1–42 could be observed, demonstrating no
plaque pathology (Fig. 2C).
7B2 Counteracts the Neurocytotoxic Effect of A1–42 and
Increases Cell Viability—To investigate whether 7B2 is neuro-
protective, we performed cell toxicity assays using Neuro-2A
cells. A 48-h treatment of Neuro-2A cells with A1–42 pro-
duced an 50% decrease in the number of living cells as
revealed by quantification of viable cells using both WST-1
assays (Fig. 3A, left panel) and calcein AM staining (right pan-
els). Inclusion of 27- and 21-kDa 7B2 in the medium of
Neuro-2A cells during A treatment significantly diminished
A-induced cell death. This effect was more pronounced when
the 27-kDa form of 7B2 was added and was dose-dependent.
A1–42-induced cell death was completely prevented when
27-kDa 7B2 was added to the medium together with A1–42.
Neither of the negative controls, carbonic anhydrase (a simi-
larly sized cytosolic protein) or -lactalbumin (an irrelevant
secreted protein), reduced A neurotoxicity; however, -crys-
tallin, a known chaperone for A (31, 32), was also able to block
toxicity (data not shown).
To determine whether endogenously expressed 7B2 can also
prevent A neurotoxicity, we overexpressed 7B2 via adenoviral
infection of Neuro-2A cells. A neuroprotective effect was
observed when 7B2 was overexpressed by 3-fold (Fig. 3B),
resulting in a significant increase in living cells, which reached
7B2 Inhibits Protein Aggregation
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85% of untreated controls; these results indicate that endog-
enously expressed 7B2 can rescue cells from A1–42-induced
neurotoxicity (Fig. 3C). In a parallel experiment, we decreased
intracellular 7B2 levels using 7B2-specific siRNA. The
siRNA-induced decrease in 7B2 was accompanied by a similar
decrease in the number of viable Neuro-2A cells; control oligo-
nucleotides showed no such deleterious effect. We observed
some co-localization of exogenously added recombinant His-
tagged 7B2 with Alexa Fluor-labeled A1–42 within Neuro-2A
cells (Fig. 3D), indicating cellular uptake of both proteins into
the cytosol of Neuro-2A cells.
7B2 Inhibits the Fibrillation of A1–42, A1–40, and -Sy-
nuclein in Vitro—To elucidate themolecularmode of action by
which 7B2 inhibits the formation of cytotoxic A species and to
obtain structure-function information, we performed in vitro
fibrillation assays. The addition of full-length 27-kDa 7B2
(structure shown in Fig. 4A) inhibited the fibrillation of A1–42
at 7B2:A1–42 molar ratios of 1:10. Structure-function analysis
using truncated forms of 7B2 revealed that this anti-aggrega-
tion effect was greatest when the protein was full-length (Fig.
4B) and moreover was dose-dependent (Fig. 4C). In agreement
with these findings, the majority of A1–42 became insoluble
during the course of the fibrillation assay, as shown by dot blot
analysis of centrifugally separated A1–42 fibrillation reaction
samples, which indicated greater formation of aggregates fol-
lowing 48 h of incubation (Fig. 4D). However, the ratio of solu-
ble/lighter A1–42 to insoluble/heavier A1–42 oligomers
(supernatant:pellet) shifted to favor soluble A1–42 species
when reactions were co-incubated with either 21- or 27-kDa
7B2, suggesting inhibition of the generation of larger fibrils by
these proteins. Blockade of fibril formation was independently
substantiated by quantification of transmission electronmicro-
scope images of A1–42 fibrils and oligomers (Fig. 4E) incu-
bated at 37 °C for 48 h, which demonstrated a substantial
decrease in fibril length when 27-kDa 7B2 was added to the
reaction. Although fibrils in the untreated A1–42 samples
reached an average length of 575 302 nm (mean S.D., n
10) following incubation, fibril length decreased by 80%
when 7B2 was included in the reaction (to 124 233 nm). In
these samples, we also observed an increase in the number of
smaller spherical A1–42 aggregates with an average diame-
ter of 10  4 nm.
The addition of 7B2 to preincubated A1–42 samples (at the
time point indicated by an arrow) did not result in the disinte-
gration of preformed A1–42 fibrils (Fig. 5A), indicating that
7B2 does not function as a disaggregase. However, consistent
FIGURE 1. 7B2 co-localizes with amyloid plaque pathology. A, the hippocampus of a 12-month-old mutant APP/PSEN1 mouse strongly stained for A1–42
immunoreactivity. A composite image shows significant overlap between A1–42 (green)and 7B2 (red) immunoreactivity, resulting in a yellow color in the
merged image (arrows). Scale bars100m.B, staining showing significant co-localization (overlap resulting inpurplehue)of 7B2 (red)withA1–42 (green) and
genuine extracellular plaques (blue) in the cortices of APP/PSEN1 mice. Plaques were visualized by staining with the in vivo amyloid-imaging fluorophore
methoxy-X04.
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with its effects on A1–42 fibrillation, 7B2 also inhibited the
formation of A1–40 (Fig. 5B) and -synuclein fibrils (Fig. 5C).
A dose-dependent relationship was observed for blockade of
-synuclein fibrillation by 27-kDa 7B2 (Fig. 5D).
We next aimed to determine whether 7B2 exhibits ATP-de-
pendent chaperone-like refolding properties similar to those of
larger chaperones such as members of the HSP70 and HSP90
families. Although denatured luciferase was efficiently refolded
FIGURE 2. Co-localization of 7B2 with extra- and intracellular protein aggregates in AD hippocampus and PD Lewy bodies. A, AD brain: schematic
representation of 7B2 immunoreactivity (red stars) and A-positive plaques (green stars) as detected throughout the extent of the human brain sample at the
level of the hippocampus. Upper panels, lowmagnification images provide an overview of the areas of A-immunoreactive deposits (red) and 7B2 expression
(green) within in the hippocampus. Lower panel, highmagnification image of representative amyloid plaqueswithin the hippocampus confirms a high degree
of co-localization (arrowhead) of 7B2 immunoreactivity with A immunoreactivity. B, PD brain: 7B2 immunoreactivity (red stars) was found throughout the
mesencephalon, whereas Lewy bodies were confined to the substantia nigra (green stars).Upper panels, lowmagnification images provide an overview of the
areas of -synuclein-immunoreactive deposits in Lewy bodies (green) and 7B2 expression (red) within the substantia nigra. Lower panel, high magnification
image of representative Lewy bodies within the substantia nigra confirms a high degree of co-localization (arrowhead) of 7B2 immunoreactivity with -sy-
nuclein immunoreactivity. The majority of 7B2 immunoreactivity was confined to areas near the nucleus, suggesting intracellular localization. C, 7B2 immu-
noreactivity was detected in a human control brain sample. Shown are representative images of the hippocampus in a non-diseased control brain. Although
only limitedA immunoreactivity (red) andnoplaqueburdenwere detected,weobserved significant 7B2 immunoreactivity (green) thatwas confined to areas
near cell nuclei, suggesting intracellular localization. CA, cerebral aqueduct; CT, corticopontine tract; Hp, hippocampus; LN, lentiform nucleus;MRF, mesence-
phalic reticular formation; PT, pyramidal tract; RN, red nucleus; SN, substantia nigra; TH; thalamus. Scale bars 10 m.
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by HSP70, restoring about half of its enzymatic function, 7B2
displayed no significant refolding activity (Fig. 6).
The small molecular mass of 7B2 potentially qualifies this
protein to be classified as a small heat shock protein; these
chaperone proteins possess masses between 15 and 40 kDa and
share the conserved sequence known as the -crystallin
domain (33). However, multisequence alignment using 3D/T-
CoffeeWeb server tools revealed no significant sequence iden-
tity to either -crystallin itself or the comparably sized heat
shock protein sHSP27 (data not shown).
DISCUSSION
Neurodegenerative diseases such as AD and PD have been
established as “protein-folding disorders,” the etiology of which
involves the aggregation of non-native protein conformations,
resulting in extracellular and intracellular protein aggregates
(34). The abundance of these protein aggregates in neurode-
generative disease is, however, difficult to explain and appears
to represent an essential failure of neuronal chaperone systems
to sustain native protein conformation. The particular toxicity
of protein aggregates in the nervous system implies that neu-
rons may require special mechanisms to maintain continuous
chaperone control of protein aggregation during secretory
pathway transit, granule residence, and even following secre-
tion and reuptake, yet few specifically neuronal secretory chap-
erone mechanisms have been described.
Although 7B2 has long been recognized as an excellent neu-
roendocrinemarker involved in PC2-mediated peptide synthe-
sis (13, 14), its widespread neuronal distribution within the
brain, and also in areas lacking prohormone convertases (15),
strongly suggests non-convertase-related functions. Our
immunohistochemical data show clear co-localization of 7B2
FIGURE 3. 7B2 decreases A-induced cell death in Neuro-2A cells. A, Neuro-2A cells were treated with 10 M A1–42 for 48 h to induce cell death in the
presence or absence of 7B2. Left panel, quantification of A-induced cell death by theWST-1 cell viability assay. Right panels, representative photomicrographs
showingviable calceinAM-stainedNeuro-2Acells following treatmentwithA1–42withorwithout 7B2.ns, not significant.B, quantificationof endogenous7B2
levels inNeuro-2A cells by radioimmunoassay following either adenoviral (AV) overexpression or RNAi-mediated knockdown. cont., control.C, A1–42-induced
cell death followingmanipulation of intracellular 7B2 levelswasmonitoredusing theWST-1 cell viability assay.D, exogenously added recombinantHis-tagged
7B2 (green arrows) was internalized and co-localizedwith Alexa Fluor-labeled A1–42 (red) in Neuro-2A cells, indicating co-uptake into the cytosol of Neuro-2A
cells (yellow arrows). Anti-His tag antiserum was used for the experiment in D.
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FIGURE 4. Structure-function analysis of 7B2 proteins in suppressing A fibrillation. A, upper, amino acid sequence of rat 7B2 including the N-terminal
signal peptide and theC-terminal inhibitorypeptidedomain. Putativepost-translationalmodification sites aremarked (red P, knownphosphorylation site;blue
P, hypothetical phosphorylation site; black S, sulfation; S-S, disulfide bond); the C-terminal cleavage site is underlined; and the minimal amino acid sequence
required for PC2 activation is boxed. The first and last three amino acids of the 7B2 fragments used in this study are indicated in boldface. Lower, domain
structure of 7B2 and schematic representation of the N-terminal deletions and peptides used in this study. B, A1–42 (20 M) was incubated with either
full-length 7B2 (27 kDa; red) or truncated proteins and peptides (2 M). Protein fibrillation was monitored using a ThT fibrillation assay. C, the inhibition of
A1–42 aggregation in the presence of 27-kDa 7B2 was dose-dependent and was most effective at a 7B2:A1–42 molar ratio of 1:10. D, quantification of
supernatant (soluble A1–42) versus pellet (insoluble A1–42) dot intensities revealed a ratio shift (supernatant:pellet) toward the soluble A1–42 species
following the addition of 7B2. AU, absorbance units. E, quantification of A1–42 fibril formation observed after 72 h of incubation in reactions with or without
7B2 by transmission electron microscopy. ***, p 0.001.
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with aggregated proteins in neurodegenerative disease, indicat-
ing a potential functional relationship. A similar accumulation
of chaperones within amyloid-like plaques in the brains of AD
and PD patients has been reported for -crystallin, HSP47, and
clusterin (8, 35, 36). Interestingly, the distribution of immuno-
reactive 7B2 in diseased brain indicates that this protein may
possess a higher affinity for non-aggregated A1–40, A1–42,
and A1–40 and a lesser affinity for fully mature dense core
plaques. This suggests an anti-aggregation effect of 7B2 that is
temporally organized, occurring prior to compaction of A
deposits, as would be expected from a chaperone-mediated
defense response to A plaque maturation. A general associa-
tion of 7B2 with neurodegenerative protein aggregation is fur-
ther substantiated by the pronounced intracellular co-localiza-
tion of 7B2 with -synuclein-rich Lewy bodies within the
substantia nigra of a PD patient.
7B2 is found together with intracellular and extracellular
protein aggregates, implying that it could act at both locations.
We speculate that 7B2 may block inappropriate protein-pro-
tein interactions initially during intracellular protein trafficking
through the secretory pathway, extracellularly following secre-
tion of 7B2 andA, and possibly even following reuptake. Inter-
estingly, cellular reuptake of A into endosomes and lysosomes
has been reported to facilitate its aggregation (37). Here, we
have shown that Neuro-2A cells are capable of taking up added
A simultaneously with added exogenous 7B2, raising the idea
that these compartments serve as sites for 7B2 interaction with
A under physiological conditions. The cytoplasmic protein
-synuclein has been reported to be secreted and to be localized
intravesicularly in a similar fashion (38); an analogous mecha-
nism could be operative for -synuclein/7B2. However,
whether extracellular association of these proteins occurs prior
to uptake or whether both species are nonspecifically endocy-
tosed together is not yet clear.
We have further demonstrated here that added 7B2 can
block the cytotoxic effects of A peptides. Neuro-2A cells
exposed to toxic A oligomers died rapidly; inclusion of either
7B2 or -crystallin, but not the control proteins carbonic anhy-
drase and -lactalbumin, blocked the cytotoxic effects of these
oligomers. It is unlikely that fibril formation is involved in A
neurotoxicity because the concentration of A used was low
(10 M) and because A oligomers appear to be much more
toxic than fibrils (39). Thus, 7B2may function to block protein-
protein association at the oligomer level; this idea is in line with
the known ability of 7B2 to block both the oligomerization and
the aggregation of the convertase proPC2 (18).
Of great physiological importance is our observation that
modulation of intracellular 7B2 expression directly correlates
with the cytotoxicity of exogenously administered A1–42. In a
FIGURE 5. 7B2 does not disintegrate preformed mature A1–42 fibrils but suppresses A1–40 and -synuclein fibrillation. A, A1–42 (20 M) was
incubated at 37 °C, followed by the addition of 2 M 27- or 21-kDa 7B2 at the time point indicated by the arrow. Protein aggregation was monitored with the
ThT fibrillation assay. Further A1–42 aggregation was inhibited once 7B2 was added; however, preformed mature fibrils were not affected (n  3/group).
A1–40 (20 M) (B) and -synuclein (Syn; 44 M) (C) were incubated with full-length 7B2 (27 kDa; red) or 21-kDa 7B2 (blue), respectively, and fibrillation was
monitored by the ThT assay. D, dose dependence relationship for inhibition of -synuclein fibrillation by 27-kDa 7B2.
FIGURE 6. 7B2 does not possess chaperone-like refolding activity.
Unfolded and inactive firefly luciferase (40M) was incubated with either 21-
or 27-kDa 7B2 (4 M), followed by measurement of regained (refolded) lucif-
erase enzyme activity, determined by luciferin bioluminescence assay.
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similar approach, Magrané et al. (40) have shown that viral
overexpression ofHSP70 successfully rescues neurons from the
toxic effects of intracellular A accumulation. Moreover,
another study demonstrated that drug-induced chaperone
overexpression of HSP70 andHSP90maintains tau protein in a
soluble and functional conformation, preventing it from aggre-
gating (10). In line with these studies, our data indicate that a
certain level of endogenous 7B2may be sufficient to prevent the
formation of harmful A1–42 species and support the idea that
loss of neuronal 7B2might facilitateA1–42-induced neurotox-
icity. The location of 7B2 action in blocking A1–42-induced
neurotoxicity requires further investigation; it is possible that
7B2 acts both extracellularly to block oligomer formation and
intracellularly following reuptake.
In addition to these in vivo and cellular data linking 7B2 with
the toxic effects of A, we have directly demonstrated that 7B2
suppresses the fibrillation of aggregation-prone proteins in
vitro. The ability of 7B2 to act at low stoichiometric ratios with
respect to client proteins is remarkable and further supports
the idea of 7B2 involvement in A-related plaque formation.
Most protein chaperones described to date function intracel-
lularly. Only four secreted chaperones that act extracellularly
have been identified thus far: (i) the ubiquitously expressed gly-
coprotein clusterin/ApoJ, which in the brain appears to be of
glial origin (11); (ii) the heat shock-related lens protein -crys-
tallin (41); (iii) the presumed A chaperone prostaglandin D
synthase/-trace (42); and the receptor-associated protein RAP
(43). Of these, the chaperone with by far the greatest genetic
associationwith AD is clusterin (reviewed in Refs. 11 and 12). A
key feature that distinguishes 7B2 from clusterin is that clus-
terin is expressed in nearly all mammalian tissues, whereas 7B2
expression is limited to cells containing a regulated secretory
pathway: the central and peripheral nervous systems and endo-
crine/neuroendocrine systems. Interestingly, a recent study
investigating the interaction of clusterin andA using biophys-
ical approaches reported that clusterin binds to and stabilizes
A oligomers of all sizes, thereby influencing the equilibriumof
A oligomers, aggregates, and fibrils (44). It is possible that 7B2
acts via similar molecular mechanisms to decrease A protein
oligomerization, fibrillation, and cytotoxicity. The appearance
of the disc-shaped structures observed by electron microscopy
in this study seems to represent an increase in spherical A1–42
oligomers, potentially indicating that 7B2 promotes the forma-
tion of nontoxic stable off-pathway A species, similar to what
has been reported following treatment with inositol (45).
Biophysical characterization of recombinant 7B2 has shown
that it is an intrinsically disordered protein capable of oligomer-
ization (46). These properties are similar to those of certain
small anti-aggregant cytosolic heat shock proteins (reviewed in
Refs. 47 and 48), and we speculate that 7B2 may block the for-
mation of protein aggregates using similar mechanisms.
Although weak homology to chaperonin-related sequences has
been reported (17), 7B2 exhibits no significant sequence
homology to clusterin, crystallins, or small heat shock proteins.
Thus, 7B2 appears to have novel anti-aggregation domains. The
role of the known post-translational modifications of this pro-
tein, sulfation (49) and phosphorylation (50, 51) (see Fig. 4A), in
anti-aggregation remains to be established.
In summary, our data provide new insight into the function
of neuronal 7B2 and establish this protein as a novel anti-aggre-
gation chaperone strongly associated with neurodegenerative
disease. Interestingly, recent proteomics studies also point to
an association of 7B2 with various neurodegeneration-related
protein-misfolding diseases, including AD, PD, and amyo-
trophic lateral sclerosis (20–23). These observations are sup-
ported by data showing that 7B2 is significantly up-regulated in
brain tissues of ADpatients (52) and by a fifth proteomics study
inwhich 7B2was found to be elevated in the cerebrospinal fluid
of amyotrophic lateral sclerosis patients (53), indicating possi-
ble up-regulation of 7B2 as a response to increased protein
aggregation andmisfolding. Taken together with the work pre-
sented here, these studies provide support for the idea that 7B2
plays a role in the etiology of aggregate formation in neurode-
generative disease.
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